Table 3 FDA-approved medications for OUD, with typical dosing paradigms for each of the approved formulations.

FDA-approved medications for OUD, with typical dosing paradigms for each of the approved formulations.. PO, per os (oral); SL, subligual; BUC, buccal; SQ, subcutaneous; IM, intramuscular.

TreatmentDose rangeConsiderations
Methadone (PO)80–150 mg/day
(typical range)
Maintenance dosing
is determined
during the early
weeks of treatment
following upward
titration. Individual
genetic and drug
history differences
may lead to
requirement of
higher doses than
the typical range.
FDA approved in
1972.
Buprenorphine-
naloxone (SL or BUC)
8–24 mg/day
buprenorphine
(1–6 mg/day
naltrexone)
(typical range)
4:1 ratio (w/w) of
buprenorphine-
naloxone. Because
of partial agonist
nature of
buprenorphine, no
further treatment
effect to be gained
by doses greater
than 24 mg/day.
FDA approved in
2002.
Buprenorphine
extended-release
formulation (SQ)
80–300 mg/monthly
injection
Two formulations
available. FDA
approved in 2016
and 2017.
Naltrexone tablets
(PO)/extended-
release formulation
(IM)
50 or 100 mg/day
orally; 380 mg/
monthly IM
injection
Requires a patient
to be opioid free for
7–10 days before
administration. FDA
approved in 1984
(tablets, no longer
marketed); 2010
(extended release).